25E-NBOH

25E-NBOH
Clinical data
Other names	2C-E-NBOH; NBOH-2C-E
Legal status
Legal status	BR: Class F2 (Prohibited psychotropics); DE: NpSG (Industrial and scientific use only); UK: Class A;
Identifiers
	IUPAC name 2-({[2-(4-ethyl-2,5-dimethoxyphenyl)ethyl]amino}methyl)phenol;
CAS Number	1391489-79-4; hydrochloride: 1539266-40-4;
PubChem CID	135391539;
ChemSpider	95668952;
UNII	EB0KU6R3BE;
CompTox Dashboard (EPA)	DTXSID001017254 ;
Chemical and physical data
Formula	C19H25NO3
Molar mass	315.413 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CCC1=CC(=C(C=C1OC)CCNCC2=CC=CC=C2O)OC;
	InChI InChI=1S/C19H25NO3/c1-4-14-11-19(23-3)15(12-18(14)22-2)9-10-20-13-16-7-5-6-8-17(16)21/h5-8,11-12,20-21H,4,9-10,13H2,1-3H3; Key:SYBINTRPEZWFLZ-UHFFFAOYSA-N;

25E-NBOH (2C-E-NBOH, NBOH-2C-E) is a derivative of the phenethylamine derived hallucinogen 2C-E. It was first developed by Martin Hansen at the University of Copenhagen in 2010 as a brain imaging agent,^[2] but has subsequently been sold as a designer drug, first being identified in Brazil in 2018 on seized blotter paper,^[3]^[4]^[5] as well as in Slovenia^[6] and France.^[7] It acts as a potent serotonin receptor agonist with similar affinity to better-known compounds such as 25I-NBOMe at 5-HT_2A and 5-HT_2C receptors.^[8]